1. Generics Bulletin
  2. >>Market Intelligence
  3. >>Company Rankings

The Generics Bulletin Top 50, Part One: Industry Top 10 Reshaped By Leaders’ Transformations

Perrigo Rx Divestment Sees Firm Drop Out Of Top Five As Sun Rises

 
• By Dave Wallace

A new entrant into the top five global generics and biosimilars companies shows how transformations for some of the leading off-patent players are reshaping the industry landscape, with more major changes in the pipeline. We examine the 10 leaders of the pack in the first instalment of this year’s Generics Bulletin Top 50.

Generics Bulletin Top 50 2022
A new order is emerging for the leading companies • Source: Shutterstock

In the ever-evolving global generics and biosimilars industry, one constant that can be relied upon is change. Even as the upheaval of the COVID-19 pandemic recedes, fresh political and economic pressures are being felt by firms across the world, while specific local trends are also playing their part in the fortunes of regional players.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Company Rankings

Generics Bulletin’s Top 50 Ranking For 2024

 
• By Dave Wallace

This article compiles all of the data from Generics Bulletin’s 2024 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.

The Generics Bulletin Top 50, Part Three: Firms Fall Out Of Final Grouping

 
• By Dave Wallace

In the third instalment of this year’s Generics Bulletin Top 50, we look at some of the firms that have been eliminated from the bottom of our table as others have entered the picture.

The Generics Bulletin Top 50, Part Two: Major Shifts Bring Ups And Downs For Mid-Ranked Players

 
• By Dave Wallace

In the second part of Generics Bulletin’s Top 50, we see some companies rising up the rankings of generics and biosimilars players worldwide, passing others that are moving in the opposite direction.

The Generics Bulletin Top 50, Part One: Top Ten Ranking Conceals Changes For Industry Leaders

 
• By Dave Wallace

A deceptively familiar top 10 of generics and biosimilars industry leaders this year belies the significant evolutions seen for major off-patent players over the past 12 months. We reveal the changes under the surface in the first instalment of this year’s Generics Bulletin Top 50.

More from Market Intelligence

UK Gabapentin Prices Shoot Up In December

 
• By Dave Wallace

UK prices for gabapentin almost trebled in December, according to the latest figures from WaveData.

UK Memantine Prices Spike In November

 
• By Dave Wallace

Dementia treatment memantine saw the steepest rise in its UK trade price in November, according to the latest figures from WaveData.

Apixaban Prices Begin To Correct After Months Of UK Rises

 
• By Dave Wallace

After a few months of steep UK price rises for apixaban generics, October saw a correction as average prices headed in the opposite direction, the latest figures from WaveData reveal.